Equipoise: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
Equipoise | |||
Equipoise is a fundamental concept in clinical research and medical ethics, referring to a state of genuine uncertainty on the part of the clinical investigator regarding the comparative therapeutic merits of each arm in a trial. It is a critical ethical prerequisite for conducting randomized controlled trials (RCTs). | |||
==Definition== | |||
Equipoise, also known as "clinical equipoise," is the ethical basis for medical research that involves human participants. It exists when there is no consensus within the expert medical community about the preferred treatment. This uncertainty allows for the ethical justification of enrolling patients in a clinical trial, as it is believed that no patient will be knowingly disadvantaged by being assigned to any particular treatment group. | |||
==Historical Background== | |||
The concept of equipoise was first articulated by [[Benjamin Freedman]] in 1987. Freedman argued that for a clinical trial to be ethical, there must be a state of genuine uncertainty among the expert medical community about the relative therapeutic merits of each arm of the trial. This differs from "theoretical equipoise," which requires the individual investigator to be uncertain about the best treatment. | |||
==Importance in Clinical Trials== | |||
{{ | Equipoise is crucial in the design and conduct of [[randomized controlled trials]] (RCTs). It ensures that: | ||
{{ | |||
* '''[[Ethical Justification]]''': Participants are not knowingly given inferior treatment, as the trial is conducted under the assumption that the treatments being compared are equally effective. | |||
* '''[[Informed Consent]]''': Participants can be informed that there is no known superior treatment, which is essential for obtaining valid informed consent. | |||
* '''[[Scientific Validity]]''': Trials conducted under equipoise are more likely to yield scientifically valid results, as they are based on genuine uncertainty. | |||
==Challenges to Equipoise== | |||
Maintaining equipoise can be challenging, especially as new evidence emerges during the course of a trial. If one treatment begins to show clear superiority, the ethical justification for continuing the trial may be questioned. This can lead to: | |||
* '''[[Early Termination]]''': Trials may be stopped early if interim results indicate a clear benefit or harm. | |||
* '''[[Protocol Amendments]]''': Adjustments to the trial design may be necessary to maintain ethical standards. | |||
==Criticisms and Debates== | |||
Some critics argue that equipoise is difficult to achieve in practice, as individual investigators may have biases or preferences based on their clinical experience. Others suggest that the concept of equipoise should be expanded to include patient preferences and values, not just clinical uncertainty. | |||
==Also see== | |||
* [[Randomized controlled trial]] | |||
* [[Informed consent]] | |||
* [[Medical ethics]] | |||
* [[Clinical research]] | |||
{{Medical ethics}} | |||
{{Clinical research}} | |||
[[Category:Medical ethics]] | |||
[[Category:Clinical research]] | |||
[[Category:Randomized controlled trials]] | |||
Latest revision as of 22:28, 11 December 2024
Equipoise
Equipoise is a fundamental concept in clinical research and medical ethics, referring to a state of genuine uncertainty on the part of the clinical investigator regarding the comparative therapeutic merits of each arm in a trial. It is a critical ethical prerequisite for conducting randomized controlled trials (RCTs).
Definition[edit]
Equipoise, also known as "clinical equipoise," is the ethical basis for medical research that involves human participants. It exists when there is no consensus within the expert medical community about the preferred treatment. This uncertainty allows for the ethical justification of enrolling patients in a clinical trial, as it is believed that no patient will be knowingly disadvantaged by being assigned to any particular treatment group.
Historical Background[edit]
The concept of equipoise was first articulated by Benjamin Freedman in 1987. Freedman argued that for a clinical trial to be ethical, there must be a state of genuine uncertainty among the expert medical community about the relative therapeutic merits of each arm of the trial. This differs from "theoretical equipoise," which requires the individual investigator to be uncertain about the best treatment.
Importance in Clinical Trials[edit]
Equipoise is crucial in the design and conduct of randomized controlled trials (RCTs). It ensures that:
- Ethical Justification: Participants are not knowingly given inferior treatment, as the trial is conducted under the assumption that the treatments being compared are equally effective.
- Informed Consent: Participants can be informed that there is no known superior treatment, which is essential for obtaining valid informed consent.
- Scientific Validity: Trials conducted under equipoise are more likely to yield scientifically valid results, as they are based on genuine uncertainty.
Challenges to Equipoise[edit]
Maintaining equipoise can be challenging, especially as new evidence emerges during the course of a trial. If one treatment begins to show clear superiority, the ethical justification for continuing the trial may be questioned. This can lead to:
- Early Termination: Trials may be stopped early if interim results indicate a clear benefit or harm.
- Protocol Amendments: Adjustments to the trial design may be necessary to maintain ethical standards.
Criticisms and Debates[edit]
Some critics argue that equipoise is difficult to achieve in practice, as individual investigators may have biases or preferences based on their clinical experience. Others suggest that the concept of equipoise should be expanded to include patient preferences and values, not just clinical uncertainty.
Also see[edit]
| Bioethics | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|